Human monoclonal antibodies to West Nile virus identify epitopes on the prM protein

Virology

Volumn 410, Issue 1, 2011, Pages 30-37

  Calvert, Amanda E ^a   Kalantarov, Gavreel F ^b   Chang, Gwong Jen J ^a   Trakht, Ilya ^b   Blair, Carol D ^c   Roehrig, John T ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b Columbia University ^*  (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Flavivirus; Human monoclonal antibodies; Pre membrane protein; West Nile virus

Indexed keywords

EPITOPE; LEUCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2E8; MONOCLONAL ANTIBODY 5G12; MONOCLONAL ANTIBODY 8G8; PREMEMBRANE PROTEIN; TETANUS ANTIBODY; THREONINE; UNCLASSIFIED DRUG; VALINE; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HYBRIDOMA CELL CULTURE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTECTION; SITE DIRECTED MUTAGENESIS; VIRUS LIKE AGENT; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; EPITOPES; HUMANS; HYBRIDOMAS; INTERFERONS; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; VIRAL ENVELOPE PROTEINS; WEST NILE VIRUS;

FLAVIVIRUS; MUS; WEST NILE VIRUS;

EID: 78650737097     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.10.033     Document Type: Article

References (44)

1. Beigel J.H., Nordstrom J.L., Pillemer S.R., Roncal C., Goldwater D.R., Li H., Holland P.C., Johnson S., Stein K., Koenig S. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob. Agents Chemother. 2010, 54(6):2431-2436.
2. Beltramello M., Williams K.L., Simmons C.P., Macagno A., Simonelli L., Quyen N.T., Sukupolvi-Petty S., Navarro-Sanchez E., Young P.R., de Silva A.M., Rey F.A., Varani L., Whitehead S.S., Diamond M.S., Harris E., Lanzavecchia A., Sallusto F. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010, 8(3):271-283.
3. Bray M., Lai C.J. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 1991, 185(1):505-508.
4. Calvert A.E., Huang C.Y., Kinney R.M., Roehrig J.T. Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J. Gen. Virol. 2006, 87(Pt 2):339-346.
5. Cherrier M.V., Kaufmann B., Nybakken G.E., Lok S.M., Warren J.T., Chen B.R., Nelson C.A., Kostyuchenko V.A., Holdaway H.A., Chipman P.R., Kuhn R.J., Diamond M.S., Rossmann M.G., Fremont D.H. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 2009, 28(20):3269-3276.
6. Crill W.D., Chang G.J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 2004, 78(24):13975-13986.
7. Crill W.D., Trainor N.B., Chang G.J. A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles. J. Gen. Virol. 2007, 88(Pt 4):1169-1174.
8. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., Bowen R., Bunning M.L. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 2001, 75(9):4040-4047.
9. Dejnirattisai W., Jumnainsong A., Onsirisakul N., Fitton P., Vasanawathana S., Limpitikul W., Puttikhunt C., Edwards C., Duangchinda T., Supasa S., Chawansuntati K., Malasit P., Mongkolsapaya J., Screaton G. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328(5979):745-748.
10. Fischl W., Elshuber S., Schrauf S., Mandl C.W. Changing the protease specificity for activation of a flavivirus, tick-borne encephalitis virus. J. Virol. 2008, 82(17):8272-8282.
11. Huang C.Y., Butrapet S., Pierro D.J., Chang G.J., Hunt A.R., Bhamarapravati N., Gubler D.J., Kinney R.M. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J. Virol. 2000, 74(7):3020-3028.
12. Huang K.J., Yang Y.C., Lin Y.S., Huang J.H., Liu H.S., Yeh T.M., Chen S.H., Liu C.C., Lei H.Y. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol. 2006, 176(5):2825-2832.
13. Huang K.C., Lee M.C., Wu C.W., Huang K.J., Lei H.Y., Cheng J.W. Solution structure and neutralizing antibody binding studies of domain III of the dengue-2 virus envelope protein. Proteins 2008, 70(3):1116-1119.
14. Hunt A.R., Cropp C.B., Chang G.J. A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen. J. Virol. Meth. 2001, 97(1-2):133-149.
15. Hunt A.R., Frederickson S., Hinkel C., Bowdish K.S., Roehrig J.T. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J. Gen. Virol. 2006, 87(Pt 9):2467-2476.
16. Hunt A.R., Frederickson S., Maruyama T., Roehrig J.T., Blair C.D. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl.Trop. Dis. 2010, 4(7):e739.
17. Kalantarov G.F., Rudchenko S.A., Lobel L., Trakht I. Development of a fusion partner cell line for efficient production of human monoclonal antibodies from peripheral blood lymphocytes. Hum. Antibodies 2002, 11(3):85-96.
18. Kaufman B.M., Summers P.L., Dubois D.R., Cohen W.H., Gentry M.K., Timchak R.L., Burke D.S., Eckels K.H. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 1989, 41(5):576-580.
19. Keelapang P., Sriburi R., Supasa S., Panyadee N., Songjaeng A., Jairungsri A., Puttikhunt C., Kasinrerk W., Malasit P., Sittisombut N. Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. J. Virol. 2004, 78(5):2367-2381.
20. Kirman I., Kalantarov G.F., Lobel L.I., Hibshoosh H., Estabrook A., Canfield R., Trakht I. Isolation of native human monoclonal autoantibodies to breast cancer. Hybrid. Hybridomics 2002, 21(6):405-414.
21. Li L., Lok S.M., Yu I.M., Zhang Y., Kuhn R.J., Chen J., Rossmann M.G. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008, 319(5871):1830-1834.
22. Lin Y.J., Wu S.C. Histidine at residue 99 and the transmembrane region of the precursor membrane prM protein are important for the prM-E heterodimeric complex formation of Japanese encephalitis virus. J. Virol. 2005, 79(13):8535-8544.
23. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr. Opin. Immunol. 2008, 20(4):450-459.
24. Mackenzie J.S., Gubler D.J., Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 2004, 10(12 Suppl):S98-S109.
25. Nelson S., Jost C.A., Xu Q., Ess J., Martin J.E., Oliphant T., Whitehead S.S., Durbin A.P., Graham B.S., Diamond M.S., Pierson T.C. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 2008, 4(5):e1000060.
26. Obijeski J.F., Bishop D.H., Murphy F.A., Palmer E.L. Structural proteins of La Crosse virus. J. Virol. 1976, 19(3):985-997.
27. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., Gorlatov S., Mehlhop E., Marri A., Chung K.M., Ebel G.D., Kramer L.D., Fremont D.H., Diamond M.S. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 2005, 11(5):522-530.
28. Pierson T.C., Xu Q., Nelson S., Oliphant T., Nybakken G.E., Fremont D.H., Diamond M.S. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 2007, 1(2):135-145.
29. Purdy D.E., Chang G.J. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. Virology 2005, 333(2):239-250.
30. Purdy D.E., Noga A.J., Chang G.J. Noninfectious recombinant antigen for detection of St. Louis encephalitis virus-specific antibodies in serum by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 2004, 42(10):4709-4717.
31. Randolph V.B., Winkler G., Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 1990, 174(2):450-458.
32. Rodenhuis-Zybert I.A., van der Schaar H.M., da Silva Voorham J.M., van der Ende-Metselaar H., Lei H.Y., Wilschut J., Smit J.M. Immature dengue virus: a veiled pathogen?. PLoS Pathog. 2010, 6(1):e1000718.
33. Rudchenko S., Scanlan M., Kalantarov G., Yavelsky V., Levy C., Estabrook A., Old L., Chan G.L., Lobel L., Trakht I. A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen. BMC Cancer 2008, 8:248.
34. Schalich J., Allison S.L., Stiasny K., Mandl C.W., Kunz C., Heinz F.X. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J. Virol. 1996, 70(7):4549-4557.
35. Schieffelin J.S., Costin J.M., Nicholson C.O., Orgeron N.M., Fontaine K.A., Isern S., Michael S.F., Robinson J.E. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol. J. 2010, 7(1):28.
36. Tan T.T., Bhuvanakantham R., Li J., Howe J., Ng M.L. Tyrosine 78 of premembrane protein is essential for assembly of West Nile virus. J. Gen. Virol. 2009, 90(Pt 5):1081-1092.
37. Thibodeaux B.A., Roehrig J.T. Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies. Clin. Vaccine Immunol. 2009, 16(5):679-685.
38. Traggiai E., Becker S., Subbarao K., Kolesnikova L., Uematsu Y., Gismondo M.R., Murphy B.R., Rappuoli R., Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 2004, 10(8):871-875.
39. Trainor N.B., Crill W.D., Roberson J.A., Chang G.J. Mutation analysis of the fusion domain region of St. Louis encephalitis virus envelope protein. Virology 2007, 360(2):398-406.
40. Tsurushita N., Hinton P.R., Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods 2005, 36(1):69-83.
41. van den Broek M.F., Muller U., Huang S., Aguet M., Zinkernagel R.M. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 1995, 69(8):4792-4796.
42. Vazquez S., Guzman M.G., Guillen G., Chinea G., Perez A.B., Pupo M., Rodriguez R., Reyes O., Garay H.E., Delgado I., Garcia G., Alvarez M. Immune response to synthetic peptides of dengue prM protein. Vaccine 2002, 20(13-14):1823-1830.
43. Yamshchikov G., Borisevich V., Seregin A., Chaporgina E., Mishina M., Mishin V., Kwok C.W., Yamshchikov V. An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology 2004, 330(1):304-312.
44. Yu I.M., Holdaway H.A., Chipman P.R., Kuhn R.J., Rossmann M.G., Chen J. Association of the pr peptides with dengue virus at acidic pH blocks membrane fusion. J. Virol. 2009, 83(23):12101-12107.